Skip to main content
Have a personal or library account? Click to login
N-Phthaloyl-glycine-hydroxamic acid as serum iron chelator in rats Cover

N-Phthaloyl-glycine-hydroxamic acid as serum iron chelator in rats

Open Access
|May 2008

References

  1. G. Papanikolaou and K. Pantopoulos, Iron metabolism and toxicity,202 (2005) 199-211; DOI: 10.1016/j.taap.2004.06.021.
  2. E. Beutler, Iron storage disease: Facts, fiction and progress,39 (2007) 140-147; DOI: 10.1016/j.bcmd.2007.03.009.
  3. T. B. Chaston, and D. R. Richardson, Iron chelators for the treatment of iron overload disease: Relationship between structure, redox activity, and toxicity,73 (2003) 200-210; DOI: 10.1002/ajh.10348.
  4. H. Boukhalfa and A. L. Crumbliss, Chemical aspects of siderophore mediated iron transport,15 (2002) 325-339; DOI: 10.1023/A:1020218608266.
  5. J. Matijević-Sosa and Z. Cvetnić, Antimicrobial activity of-phthaloylamino-hydroxamates,55 (2005) 387-399.
  6. E. M. F. Muri, M. J. Nieto, R. D. Sindelar and J. S. Williamson, Hydroxamic acids as pharmacological agents,9 (2002) 1631-1653.
  7. A. Kleeman, J. Engel, B. Kutscher and D. Reichert,, 4ed., Thieme Medical Publishers, Stuttgart 2001.
  8. J. Matijević-Sosa and Lj. Butula, Synthesis and mitodepressive activity of some phthalimidoal-kanehydroxamic acids,43 (1993) 185-194.
  9. C. A. Burtis and E. R. Ashwood,in, WB Saunders Company, Philadelphia 1994, pp. 2059-2065.
  10. D. A. Brown, K. M. Herlihy and S. K. O'Shea, Kinetics of iron(III) chelation from polynuclear oxo-hydroxy aggregates by hydroxamic acids: Understanding ferritin iron (III) sequestration,38 (1999) 3198-3202; DOI: 10.1021/ic990158o.
  11. R. C. Hider, Z. D. Liu and S. Piyamongkol, Design and properties of 3-hydroxypyridin-4-one iron chelators with high Fe(3+) values,23 (2000) 201-209; DOI: 10.1016/S0955-3886(00)00090-4.
  12. E. Farkas, É. A. Enyedy and I. Fábián, New insight into the oxidation of Fe(II) by desferrioxamine B (DFB),6 (2003) 131-134; DOI: 10.1016/S1387-7003(02)00703-7.
  13. N. Gálvez, B. Ruiz, R. Cuesta, E. Colacio and J. M. Dominquez-Vera, Release of iron ferritin by aceto- and benzohydroxamic acids,44 (2005) 2706-2709; DOI: 10.1021/ic048840s.
  14. M. Porcu, N. Landis, S. Salis, M. Corda, P. Orru, E. Serra, B. Usai, G. Matta and R. Galanello, Effect of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure,9 (2007) 320-322.
  15. F. Aucella, M. Vigilante, P. Scalzulli, P. Musto, M. Prencipe, G. L. Valente, M. Carotenuto and C. Stallone, Synergistic effect of desferrioxamine and recombinant erythropoietin on erythroid precursor proliferation in chronic renal failure,14 (1999) 1171-1175.
  16. N. T. V. Le and D. R. Richardson, Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation,104 (2004) 2967-2975; DOI: 10.1182/blood-2004-05-1866.
  17. D. R. Richardson and P. Ponka, Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease,131 (1998) 306-315; DOI: 10.1016/S0022-2143(98)90180-9.
DOI: https://doi.org/10.2478/v10007-008-0010-7 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Language: English, Croatian
Page range: 231 - 236
Published on: May 30, 2008
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Related subjects:

© 2008 Julija Matijević-Sosa, Ita Samaržija, Lorena Honović, Blaženka Jurišić, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons License.